Dual mTOR inhibition demonstrates antiproliferative and chemosensitizing effects in chemoresistant high-grade papillary serous ovarian cancer

被引：0
|
作者：
Musa, F. [1 ]
Giuroiu, I. [1 ]
Blank, S. [1 ]
Korets, S. [1 ]
Curtin, J. [1 ]
Schneider, R. [2 ]
机构：
[1] NYU, Langone Med Ctr, New York, NY USA
[2] NYU, Sch Med, New York, NY USA
来源：
GYNECOLOGIC ONCOLOGY | 2013年 / 131卷 / 01期
关键词：
D O I：
10.1016/j.ygyno.2013.04.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：278 / 278
页数：1
相关论文
共 50 条
  • [1] mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer
    Musa, Fernanda
    Alard, Amandine
    David-West, Gizelka
    Giuroiu, Iulia
    Blank, Stephanie
    Pothuri, Bhavana
    Curtin, John P.
    Schneider, Robert
    CANCER RESEARCH, 2014, 74 (19)
  • [2] mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer
    Musa, F.
    Alard, A.
    Blank, S.
    Pothuri, B.
    Curtin, J.
    Schneider, R.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 434 - 435
  • [3] Investigation of DNA Repair and the Epigenome in Chemoresistant High-Grade Serous Ovarian Cancer
    Wong-Brown, Michelle W.
    Lombard, Janine
    van der Westhuizen, Andre
    Bowden, Nikola A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 29 - 30
  • [4] Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Matthews, Bayley G.
    Bowden, Nikola A.
    Wong-Brown, Michelle W.
    CANCERS, 2021, 13 (23)
  • [5] Drug repurposing to target TGF-β in chemoresistant high-grade serous ovarian cancer
    Wong-Brown, Michelle W. Y.
    Johnson, Zlata
    Salem, Saad
    Matthews, Bayley G.
    Ford, Caroline E.
    Marsh, Deborah J.
    Bowden, Nikola A.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [6] Characterizing chromosome instability in chemonaive, chemosensitive, and chemoresistant high-grade serous ovarian cancer.
    Morden, Claire
    Farrell, Ally
    Sliwowski, Mirka
    Lichtensztejn, Zelda
    Nachtigal, Mark
    McManus, Kirk
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 47 - 48
  • [7] Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer
    Andorfer, Peter
    Heuwieser, Alexander
    Heinzel, Andreas
    Lukas, Arno
    Mayer, Bernd
    Perco, Paul
    BMC SYSTEMS BIOLOGY, 2016, 10
  • [8] Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer
    Martins, F. C.
    Couturier, D-L
    de Santiago, I.
    Vias, M.
    Sanders, D.
    Piskorz, A.
    Hall, J.
    Jimenez-Linan, M.
    Hosking, K.
    Crawford, R.
    Brenton, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Comprehensive Genomic Characterization in Ovarian Low-Grade and Chemosensitive and Chemoresistant High-Grade Serous Carcinomas
    Jaliffa, Carolina
    Rogel, Uwe
    Sen, Indrani
    Singer, Gad
    ONCOLOGY, 2024, 102 (11) : 979 - 987
  • [10] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
12345